OTCMKTS:MEDIF MediPharm Labs (MEDIF) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free MEDIF Stock Alerts $0.06 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.0752-Week Range$0.04▼$0.08Volume236,850 shsAverage Volume112,826 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get MediPharm Labs alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About MediPharm Labs Stock (OTCMKTS:MEDIF)MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada and internationally. The company formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. It also provides GMP flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll products. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.Read More MEDIF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDIF Stock News HeadlinesApril 17, 2024 | finance.yahoo.comMediPharm Labs Corp. (MEDIF)March 29, 2024 | seekingalpha.comMediPharm Labs Corp. (MEDIF) Q4 2023 Earnings Call TranscriptApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 27, 2024 | investorplace.comMEDIF Stock Earnings: MediPharm Labs Reported Results for Q4 2023March 27, 2024 | prnewswire.comMediPharm Labs Provides Conference Call Recording DetailsMarch 27, 2024 | prnewswire.comMediPharm Labs Reports Fourth Quarter and Full Year ResultsMarch 25, 2024 | prnewswire.comMediPharm Labs Provides Update on German Cannabis LegalizationFebruary 7, 2024 | finanznachrichten.deMediPharm Labs Inc.: MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health AuthorityApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 7, 2024 | finance.yahoo.comMediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health AuthorityNovember 14, 2023 | benzinga.comMediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial ReportNovember 14, 2023 | msn.comMediPharm Labs reports Q3 resultsOctober 25, 2023 | finance.yahoo.comMediPharm Labs Corp (MLZ.BE)October 25, 2023 | finance.yahoo.comMediPharm Labs Update on $9M Settlement Agreement - All Tilray Shares Sold and Converted to CashSeptember 20, 2023 | benzinga.comMediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's NextAugust 31, 2023 | finance.yahoo.comMediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia PatientsAugust 14, 2023 | benzinga.comCannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The DetailsAugust 14, 2023 | finanznachrichten.deMediPharm Labs Corp.: MediPharm Labs Reports Second Quarter Results with Doubling of Revenue and Record Margin GrowthAugust 10, 2023 | finance.yahoo.comMediPharm Labs Sets Date to Report Second Quarter 2023 Financial ResultsAugust 1, 2023 | benzinga.comMediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA StatusAugust 1, 2023 | finance.yahoo.comMediPharm Labs Makes First Delivery of Cannabis Clinical Trial Material to US Research Partner and Provides Update on US FDA StatusJune 26, 2023 | msn.comTwo Pot Companies Continue To Focus On Cannabinoid-Based Self-Emulsifying Drug Delivery SystemsJune 22, 2023 | finance.yahoo.comMediPharm Labs Announces Change of AuditorJune 9, 2023 | fool.comMediPharm Labs (OTC: MEDIF)May 10, 2023 | finance.yahoo.comMediPharm Labs Sets Date to Report First Quarter 2023 Financial ResultsMay 6, 2023 | theglobeandmail.comClosing Bell: Medipharm Labs Corp flat on Friday (LABS)April 25, 2023 | theglobeandmail.comClosing Bell: Medipharm Labs Corp flat on Tuesday (LABS)See More Headlines Receive MEDIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediPharm Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MEDIF CUSIPN/A CIKN/A Webwww.medipharmlabs.com Phone(705) 719-7425FaxN/AEmployees130Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. David A. PidduckCEO & DirectorMr. Keith StrachanCo-Founder & PresidentMr. Greg HunterChief Financial OfficerMr. Patrick McCutcheonFounderMr. Saravan SubramaniamVice President of Operations & Supply ChainMr. Geoffrey MarrExecutive VP & General CounselMr. Brett MoonVice President of SalesMr. Kirk BinnsExecutive Vice President of Global AccountsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors MEDIF Stock Analysis - Frequently Asked Questions How have MEDIF shares performed in 2024? MediPharm Labs' stock was trading at $0.0486 at the start of the year. Since then, MEDIF stock has increased by 19.7% and is now trading at $0.0582. View the best growth stocks for 2024 here. How do I buy shares of MediPharm Labs? Shares of MEDIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MEDIF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediPharm Labs Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
